In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes

Metabolism: Clinical and Experimental

Volumn 53, Issue 8, 2004, Pages 969-976

  Jenkins, Alicia J ^a,b,c   Thorpe, Suzanne R ^d   Alderson, Nathan L ^d   Hermayer, Kathie L ^a   Lyons, Timothy J ^a,c   King, Lowrey P ^e   Chassereau, Charlyne N ^a   Klein, Richard L ^a,f  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FRUCTOSE; LOW DENSITY LIPOPROTEIN; LYSINE;

ADULT; ARTICLE; CHEMICAL COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLYCATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

ADULT; ANTIOXIDANTS; BLOOD GLUCOSE; CHROMATOGRAPHY, AFFINITY; DIABETES MELLITUS, TYPE 1; FEMALE; GLYCOPROTEINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 3342913834     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.01.002     Document Type: Article

References (37)

1. American Diabetes Association. Diabetes Vital Statistics. 1996
2. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. N Engl J Med. 320:1989;915-924
3. Lyons T.J. Glycation and oxidation A role in the pathogenesis of atherosclerosis. Am J Cardiol. 71:1993;26B-31B
4. Lyons T.J., Patrick J.S., Baynes J.W., et al. Glycation of low density lipoprotein in patients with type I diabetes Correlations with other parameters of glycemic control. Diabetologia. 29:1986;685-689
5. Lyons T.J., Klein R.L., Baynes J.W., et al. Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic subjects The influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia. 30:1987;916-923
6. Klein R.L., Laimins M., Lopes-Virella M.F. Isolation, characterization, and metabolism of the glycated and non-glycated subfractions of low-density lipoproteins isolated from type 1 diabetic patients and nondiabetic subjects. Diabetes. 44:1995;1093-1098
7. Lyons T.J., Jenkins A.J. Glycated lipoproteins. Curr Opin Lipidol. 8:1997;174-180
8. Tsai E.D., Hirsch I.B., Brunzell J.D., et al. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 43:1994;1010-1014
9. Bowie A., Owens D., Collins P., et al. Glycosylated LDL is more sensitive to oxidation Implications for the diabetic patient? Atherosclerosis. 102:1993;63-67
10. Steinbrecher U.P., Witztum J.L. Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes. 33:1984;130-134
11. Tribble D.L., Rizzo M., Chait A., et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med. 110:2001;103-110
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 26:(suppl 1):2002;S5-S20
13. Jenkins A.J., Klein R.L., Chassereau C.N., et al. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes. 45:1996;762-767
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502
15. Requena J.R., Fu M.X., Ahmed M.U., et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoproteins. Biochem J. 322:1997;317-325
16. Otvos J.D., Jeyarajah E.J., Bennett D.W., et al. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 38:1992;1632-1638
17. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Rifai N., Warnick G.R., Dominiczak M.H. Handbook of Lipoprotein Testing. ed 2 :2000;609-623 AACC, Washington, DC
18. Penn M.S., Chisolm G.M. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 108:(suppl 1):1994;S21-29
19. Steinberg D. Modified forms of low density lipoprotein and atherosclerosis. J Intern Med. 233:1993;227-232
20. Esterbauer H., Gebicki J., Puhl H., et al. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 13:1922;341-390
21. Fu M.X., Requena J.R., Jenkins A.J., et al. The advanced glycation end-product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 271:1996;9982-9986
22. Nerlich A.G., Schleicher E.D. N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis. 144:1999;41-47
23. Imanaga Y., Sakata N., Takebayashi S., et al. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis. 150:2000;343-355
24. Anber V., Millar J.S., McConnell M., et al. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 17:1997;2507-2514
25. de Graff J., Hak-Lemmers H.L.M., Hectors M.P.C., et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb Vasc Biol. 11:1991;298-306
26. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation. 95:1997;69-75
27. Bondjers G., Wiklund O., Fager G., et al. Transfer of lipoproteins from plasma to the cell populations of the normal and atherosclerotic arterial tissue. Eur Heart J. 11:(suppl E):1990;158-163
28. Jenkins A.J., Velarde V., Klein R.L., et al. Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes. 49:2000;2160-2169
29. Agarwal A., Shiraishi F., Truong L., et al. Glycated LDL imposed oxidant stress in renal proximal tubule cells Implications in diabetic nephropathy. J Am Soc Nephrol. 9:1998;A3202-A3204
30. Ha H., Kamanna V., Kirschenbaum M., et al. Role of glycated low density lipoprotein in mesangial extracellular matrix synthesis. Kidney Int. 54:(suppl 60):1997;S54-S59
31. Zhang J., Ren S., Sun D., et al. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 18:1998;1140-1148
32. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus The Diabetes Control and Complications Trial. N Engl J Med. 329:1993;977-986
33. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes. 48:1999;383-390
34. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865
35. Jenkins A.J., Lyons T.J., Zheng D., et al. Serum lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications cohort Associations with gender and glycemia. Diabetes Care. 26:2003;810-818
36. Jenkins A.J., Lyons T.J., Zheng D., et al. Lipoproteins in the DCCT/EDIC cohort Associations with diabetic nephropathy. Kidney Int. 64:2003;817-828
37. Lyons T.J., Jenkins A.J., Zheng D., et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 45:2004;910-918